BRAF and mitogen-activated protein kinase kinase (MEK)-targeted therapies and immune checkpoint inhibitor (ICI) immunotherapy have led to remarkable improvements in response and survival outcomes in the advanced (unresectable stage III or IV melanoma) setting4,5. This evidence concerns the gene BRAF and melanoma.